ClinicalTrials.gg
Status unknownNCT02013986Updated Dec 17, 2013

Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children

A Phase 4 interventional study of etomidate and midazolam in Congenital Hydronephrosis, Congenital Choledochal Cyst and Fracture, sponsored by Du yi. Status unknown at 1 site in China. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-17.

Sponsored by Du yi · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Study summary

Etomidate is an unique drug used for induction of general anesthesia and sedation. Adrenal cortical inhibition by etomidate has received much attention. However wether the circadian rhythm and pulse secretion pattern of cortisol in children are the same as that in adults is not known. Moreover, the effect of etomidate on circadian rhythm changes and clinical outcomes has never been carefully studied in children undergoing surgery. Our hypothesis is that etomidate can relieve the changes of circadian rhythm of salivary cortisol in children for 24-48 hours,and this does not make clinical outcomes worse postoperatively.

Read the detailed description
  • Sample size assessment: Using formula to calculate the total number is 30.
  • Statistical analysis: ANOVA
  • Reporting for adverse events: During the period of study, if there is any severe adverse event happening, such as severe infection, severe low cortisol concentration threatening the patient's life we will stop the trial.
02

Conditions studied

  • Congenital Hydronephrosis
  • Congenital Choledochal Cyst
  • Fracture

Keywords

  • salivary cortisol
  • circadian rhythm
  • children
  • etomidate
03

In context

Choledochal Cyst

22 studies on the registry are indexed under Choledochal Cyst; 10 are open to participants now.

Browse Choledochal Cyst studies →

Lead sponsor

This is the only study on the registry with Du yi as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3-12 years old who are plan to undergo surgery

Exclusion criteria

Exclusion Criteria:

  • endocrine disease, blood infusion, having fever, ulcer or bleeding in the oral cavity
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    etomidate & midazolam

    a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.

    Drug: etomidate · Drug: midazolam

  • Active comparator
    midazolam & propofol

    During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.

    Drug: midazolam · Drug: propofol

Interventions

  • 0.3mg/kg IV only once during induction of general anesthesia

    Also known as: Fuerli

  • midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia

    Also known as: Liyuexi

  • 2mg/kg IV only once during induction of general anesthesia

    Also known as: Diprivan

06

What researchers measure

Primary outcomes

  1. Change from baseline in salivary cortisol at the operative day

    At the time of 8am(baseline) and at the time of 8pm in the operative day , get salivary samples to calculate the change of salivary cortisol

    Time frame: baseline(8am), 8pm

  2. Change from baseline in salivary cortisol at the first day after surgery

    At the time of 8am(baseline) and at the time of 8pm in the first day after surgery , get salivary samples to calculate the change of salivary cortisol

    Time frame: baseline(8am), 8pm

Secondary outcomes

  1. Numbers of Acquired Infection Events

    Acquired infection using extra antibiotics(not prophylactic antibiotics) after surgery.

    Time frame: up to 10 days after surgery

  2. Numbers of using inotropic drugs

    Inotropic drugs include norepinephrine, adrenaline, phenylephrine and dopamine.

    Time frame: within 3 days

  3. Days of stay in intensive care unit (ICU) after surgery

    Days of stay in ICU after surgery.

    Time frame: up to 10 days after surgery

07

Study locations

1 of 1 sites recruiting
  • department of anesthesia of Xinhua Hospital
    Shanghai, Shanghai 200092, China
    Recruiting
    • Wang Yinwei · Contact86-21-13918690528
    • Du yi · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02013986
Lead sponsor
Du yi
Responsible party
Du yi (attending of anesthesiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine) — Sponsor-investigator
First posted
Dec 17, 2013
Start date
Sep 2013
Primary completion
Jun 2014 (estimated)
Completion
Aug 2014 (estimated)
Last update
Dec 17, 2013

Study contacts

Chen yijun
Contact
86-21-13764206966
Wng Y Wei, professor
study director · Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etomidate

Start the discussion